Image Quality Enhancement: Hyperfine's new multi-direction diffusion-weighted imaging (DWI) software has received FDA clearance, significantly improving image quality for stroke detection, thereby enhancing sensitivity and specificity for smaller strokes and expanding the clinical capabilities of acute neurological care.
Clinical Application Expansion: The new DWI sequence utilizes multi-directional signal acquisition to provide clearer lesion visualization, particularly valuable in critical care settings like cardiac ICUs and emergency departments, enabling more confident detection of small stroke lesions to meet urgent clinical diagnostic needs.
Technological Innovation Milestone: The launch of this DWI software represents a significant advancement in Hyperfine's Optive AI™ software series, marking an expansion of the Swoop® system's role in stroke care and further solidifying its leading position in the portable MRI market.
Market Opportunity Capture: With the Swoop® system's combination of high-quality imaging and portability, Hyperfine is well-positioned to significantly enhance its application across various hospital care settings, capturing substantial market opportunities in the stroke diagnosis field.
HYPR
$0.9277+Infinity%1D
Analyst Views on HYPR
Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HYPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HYPR is 2.00 USD with a low forecast of 2.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.996
Low
2.00
Averages
2.00
High
2.00
Current: 0.996
Low
2.00
Averages
2.00
High
2.00
Lake Street
Buy
maintain
$2
2025-08-14
Reason
Lake Street
Price Target
$2
2025-08-14
maintain
Buy
Reason
Lake Street raised the firm's price target on Hyperfine to $2 from $1.50 and keeps a Buy rating on the shares after the company reported Q2 results and reiterated 2025 guidance for 10%-20% revenue growth. The firm believes a growth inflection supports multiple expansion, the analyst tells investors in a post-earnings note.
B. Riley
Yuan Zhi
Buy
maintain
$1
2025-06-03
Reason
B. Riley
Yuan Zhi
Price Target
$1
2025-06-03
maintain
Buy
Reason
B. Riley
Buy
downgrade
$1
2025-05-15
Reason
B. Riley
Price Target
$1
2025-05-15
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Hyperfine to $1 from $1.20 and keeps a Buy rating on the shares. The Q1 sales miss was driven by the loss of several orders at large academic institutions that were funded by research grants, which was a result of the tension between academic institutions and the current administration, the analyst tells investors in a research note. The firm awaits more clarity in the second half of 2025.
Lake Street
Frank Takkinen
Strong Buy
Initiates
$1.5
2025-03-24
Reason
Lake Street
Frank Takkinen
Price Target
$1.5
2025-03-24
Initiates
Strong Buy
Reason
About HYPR
Hyperfine, Inc. is a health technology company. The Company is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
